Skip to main content
H.R. 7035 117th Congress House

Biologics Market Transparency Act of 2022

Official title: To amend the Federal Food, Drug, and Cosmetic Act to require prompt reports of marketing status by holders of approved applications for biological products, and for other purposes.

Introduced: March 9, 2022 See on congress.gov
Health
Sign in to write a letter Sign in to watch
This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 10, 2022
Referred to the Subcommittee on Health.
Mar 9, 2022
Introduced in House
Mar 9, 2022
Referred to the House Committee on Energy and Commerce.
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action March 10, 2022

Referred to the Subcommittee on Health.

 Plain-English summary Congressional Research Service

Biologics Market Transparency Act of 2022

This bill requires biologics manufacturers to notify the Food and Drug Administration in advance of withdrawing a product from sale.

 Related & companion bills 3
  • HR 7667 Food and Drug Amendments of 2022
  • S 4348 FDASLA Act of 2022
  • S 4302 Biologics Market Transparency Act of 2022
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Lobbying activity 2

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

  • 535 GROUP, LLC
    for VISA, INC. · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
  • 535 GROUP, LLC
    for VISA, INC. · District of Columbia · 2nd Quarter 2026 (Apr 1 - June 30)

Bodies those filers lobbied

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

 Cosponsors 1
All 1 Republican 1
R
Hudson, Richard
North Carolina · Mar 9, 2022
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 7035: Biologics Market Transparency Act of 2022. 117th Congress. Open America. https://openamerica.io/bill/117-HR-7035/
MLA
"H.R. 7035: Biologics Market Transparency Act of 2022." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-7035/.
Bluebook (legal)
H.R. 7035, 117th Cong. (2026), https://openamerica.io/bill/117-HR-7035/.
Markdown link
[H.R. 7035: Biologics Market Transparency Act of 2022](https://openamerica.io/bill/117-HR-7035/)
Report a problem